Technologies
This technology is a drug treatment for Parkinson’s disease and other disorders involving the serotonin 2A receptor.
Current treatments for psychiatric and neurological disorders are not effective. Psychedelic drugs have shown great potential to improve certain brain disorders, however unwanted hallucinogenic side effects have deterred their adoption. Addressing this issue is crucial to provide patients with effective treatment options with minimal side effects for conditions like Parkinson's disease (PD) and dementia.
This technology identifies a role for Ariadne, a partial serotonin 2A receptor agonist and a psychedelic analogue, as a therapeutic treatment for Parkinson’s disease. Remarkably, Ariadne shows no hallucinogenic effects and efficiently targets PD symptoms in a mouse model. This drug proposes a safer and more efficacious treatment for a variety of neurological and psychiatric disorders involving serotonin 2A receptors.
This technology has been validated in vivo in mice.
Patent Pending
IR CU21182, CU21360, CU23079
Licensing Contact: Jerry Kokoskha